| Name | Speakers |
|---|---|
| 12:00 PM - 12:30 PM (CEST) | |
| Understanding Myc-associated Proteins to Explore Strategies to Inhibit Their Function | Martin Eilers - University of Würzburg |
| 12:30 PM - 1:00 PM (CEST) | |
| Structure, Function, and Dynamics of the Dimerisation and DNA-Binding Domain of the Oncogenic Transcription Factor Myc | Robert Konrat - University of Vienna |
| 1:30 PM - 2:00 PM (CEST) | |
| Roundtable Discussion:Exploring the Unknown Effects of Drugging Transcription Factors | Charles Lin - Kronos Bio |
| 2:10 PM - 2:40 PM (CEST) | |
| OBF1/OCT Factors as Novel Targets in Germinal Center-Derived Lymphomas | Patrick Matthias - Friedrich Miescher Institute for Biomedical Research |
| 2:40 PM - 3:10 PM (CEST) | |
| New Routes towards Small Molecule Mediated Degradation of Transcription Factors | Eric Fischer - Dana Farber Cancer Institute |
| Name | Speakers |
|---|---|
| 12:00 PM - 12:30 PM (CEST) | |
| Direct inhibition of MYC with Stabilised Antisense Oligonucleotides | Christopher Ott - Harvard Medical School |
| 12:30 PM - 1:00 PM (CEST) | |
| Attacking Myc with Cell-Penetrating Mini-Proteins | Laura Soucek - Peptomyc |
| 1:30 PM - 2:00 PM (CEST) | |
| Roundtable Discussion:Additional Strategies to Target Transcription Factors | Giorgio Galli - NIBR | Novartis |
| 2:10 PM - 2:40 PM (CEST) | |
| Drugging Oncogenic Transcription Factors with Enhancer Activity Screen | Joey Azofeifa - Arpeggio Bio |
| Name | Speakers |
|---|---|
| 12:00 PM - 12:30 PM (CEST) | |
| Identifying Inhibitors of Oncogenic Transcription Programs Through a Small Molecule Microarray Discovery Platform | Charles Lin - Kronos Bio |
| 12:30 PM - 1:00 PM (CEST) | |
| Identifying and Characterising TF Networks Dependencies in Urogenital Cancers | Giorgio Galli - NIBR | Novartis |
| 1:00 PM - 1:30 PM (CEST) | |
| Platforms for the Generation and High-Throughput Screening of Microcycle libraries for inhibitors for protein-protein and protein-DNA interactions | Ali Tavassoli - University of Southampton |
| 2:00 PM - 2:30 PM (CEST) | |
| Roundtable Discussion:Tackling the Protein-DNA and Protein-Protein binding problem | Allan Jordan - Sygnature Discovery |
| 2:40 PM - 3:10 PM (CEST) | |
| Reimagining Druggability using Chemoproteomic Platforms | Daniel Nomura - University of California, Berkeley/Vicinitas Therapeutics |
| Name | Speakers |
|---|---|
| 12:00 PM - 12:30 PM (CEST) | |
| Clinical Development of CCS1477: A First-Class Small Molecule Inhibitor to Drug Transcription | Will West - CellCentric |
| 12:30 PM - 1:00 PM (CEST) | |
| GT19077, a c-Myc/Max PPI Small molecule Inhibitor to Selectively Target c-Myc-Additive B-cell and Myeloid Malignancies | Liandong Ma - Suzhou Kintor Pharmaceuticals, Inc. |
| 1:30 PM - 2:00 PM (CEST) | |
| Roundtable Discussion:New Directions in Targeting Transcription Factors: Oncology and Beyond | Giorgio Galli - NIBR | Novartis |
| 2:10 PM - 2:40 PM (CEST) | |
| Mapping RNA Target Via Small Molecule Microarray Tools | John Schneekloth - National Cancer Institute-Frederick |